CD1D and neoplasm: Leveraging their inherent capacity for dual-targeting synergy—simultaneous engagement of protein antigens via CAR and CD1d-presented lipid antigens via their invariant TCR—coupled with robust tumor microenvironment (TME) remodeling, iNKT cells effectively overcome barriers in solid tumor therapy.